Interaction of apomorphine, neuroleptics and stimulants with alpha-methyl-m-tyramine, a false dopaminergic transmitter.
D000661:Amphetamine / Q000494:pharmacology*; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology*; D001593:Benzyl Compounds / Q000494:pharmacology; D002264:Carboxylic Acids / Q000494:pharmacology; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D003342:Corpus Striatum / Q000187:drug effects; D003913:Dextroamphetamine / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005260:Female; D006207:Half-Life; D006220:Haloperidol / Q000494:pharmacology; D007279:Injections, Subcutaneous; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D009287:Naphthyridines / Q000494:pharmacology; D010636:Phenols / Q000494:pharmacology; D051381:Rats; D013997:Time Factors; D014149:Tranquilizing Agents / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D014272:Trifluperidol / Q000494:pharmacology; D014446:Tyrosine 3-Monooxygenase / Q000037:antagonists & inhibitors
D001593:Benzyl Compounds; D002264:Carboxylic Acids; D000697:Central Nervous System Stimulants; D008996:Monoamine Oxidase Inhibitors; D009287:Naphthyridines; D010636:Phenols; D014149:Tranquilizing Agents; D000661:Amphetamine; D014446:Tyrosine 3-Monooxygenase; D006220:Haloperidol; D001058:Apomorphine; D014272:Trifluperidol; D003913:Dextroamphetamine; D004298:Dopamine